UroGen Pharma Ltd. (URGN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 24,215 | 20,254 | 25,204 | 21,848 |
| Cost of revenue | 3,550 | 2,330 | 2,453 | 2,229 |
| Gross profit | 20,665 | 17,924 | 22,751 | 19,619 |
| Research and development expenses | 18,914 | 19,871 | 11,355 | 15,402 |
| Selling, general and administrative expenses | 43,199 | 34,967 | 28,941 | 30,056 |
| Operating loss | -41,448 | -36,914 | -17,545 | -25,839 |
| Interest expense on long-term debt | 4,132 | 4,068 | 2,721 | 3,461 |
| Interest and other income, net | 1,299 | 2,114 | 2,599 | 1,708 |
| Financing on prepaid forward obligation | 4,644 | 4,583 | 5,915 | 5,773 |
| Loss before income taxes | -48,925 | -43,451 | -23,582 | -33,365 |
| Income tax expense | 1,015 | 392 | 91 | 38 |
| Net loss | -49,940 | -43,843 | -23,673 | -33,403 |
| Unrealized income (loss) on investments | -8 | -42 | 267 | 6 |
| Comprehensive loss | -49,948 | -43,885 | -23,406 | -33,397 |
| Basic and diluted loss per ordinary share (in dollars per share) | -1.05 | -0.92 | -0.55 | -0.91 |
| Weighted-average number of ordinary shares (in shares) | 47,739,816 | 47,422,119 | 43,100,237 | 36,821,915 |